表紙
市場調查報告書

心臟移植治療的全球市場:2020年∼2024年

Heart Transplantation Therapeutics Market by Product and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 919941
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
心臟移植治療的全球市場:2020年∼2024年 Heart Transplantation Therapeutics Market by Product and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年12月06日內容資訊: 英文 155 Pages
簡介

全球心臟移植治療市場上,心血管疾病和心臟衰竭的盛行率上升,複數劑型的藥物可得性,心臟移植免疫抑制劑的依賴性高等成為成長促進因素,在預測期間內預計將以約3%的年複合成長率擴大。但,免疫抑制劑的不良影響,器官移植的供需不平衡,及心臟移植伴隨的長期併發症等要素,可能妨礙在預測期間內心臟移植治療產業的成長。

本報告提供全球心臟移植治療市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2019年∼2024年)
  • 免疫抑制劑
  • 輔助藥
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 器官移植的技術出現
  • 策略性聯盟的增加
  • 器官移植的國際性合作的擴大

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Veloxis Pharmaceuticals A/S

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40272

About this market

Technavio's heart transplantation therapeutics market analysis considers sales from immunosuppressants and supplementary medications products. Our study also finds the sales of heart transplantation therapeutics in Asia, Europe, North America, and ROW. In 2019, the immunosuppressants segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as mechanism of actions (MoA) of these drugs to treat and prevent organ rejection will play a significant role in the immunosuppressants segment to maintain its market position. Also, our global heart transplantation therapeutics market report looks at factors such as rising prevalence of cardiovascular diseases and heart failures, availability of drugs in multiple dosage forms, and high dependency of immunosuppressants for heart transplantation. However, adverse effects of immunosuppressants, demand-supply imbalance for organ transplantation, and long-term complications associated with heart transplantation may hamper the growth of the heart transplantation therapeutics industry over the forecast period.

Overview

High dependency on immunosuppressants for heart transplantation

Various advances in surgical techniques, especially organ transplants and the prevalence of severe coronary artery disease and dilated cardiomyopathy are leading to an increase in the need for heart transplantation surgeries. However, heart transplantation can lead to several types of heart transplant rejection such as acute cellular rejection, acute antibody rejection, and coronary artery vasculopathy chronic rejection. This is driving the need for heart transplantation therapeutics to prevent transplant rejection. Immunosuppressants are used to prevsent transplant rejection caused by immune system. Thus, the high dependency on immunosuppressants for heart transplantation will lead to the expansion of the global heart transplantation therapeutics market at a CAGR of almost 3% during the forecast period.

Advent of techniques for organ transplantation

The number of heart transplantation procedures is substantially high, especially in developed countries, due to the high prevalence of risk factors for heart impairment. Currently, the market is witnessing rapid development in the field of regenerative therapies, such as cell therapy, gene therapy, and tissue engineering, which also involve the development of heart and/or other organs. The introduction of novel approaches for heart regeneration and transplantation is one of the key heart transplantation therapeutics market trends. Organ printing is a modern technology, which is a layer-by-layer additive robotic bio-fabrication of 3D functional living macro tissues and organ constructs using tissue spheroids as building blocks. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global heart transplantation therapeutics market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global heart transplantation therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading heart transplantation therapeutics manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Veloxis Pharmaceuticals A/S.

Also, the heart transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Immunosuppressants - Market size and forecast 2019-2024
  • Supplementary medications - Market size and forecast 2019-2024
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Advent of techniques for organ transplantation
  • Increasing strategic alliances
  • Growing international collaborations for organ transplantation

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Veloxis Pharmaceuticals A/S

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendor key offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Product - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Immunosuppressants - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Immunosuppressants - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Supplementary medications - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Supplementary medications - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2019-2024 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Objectives of European Patients' Forum
  • Exhibit 35: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of total population)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Benefits of multiple dosage forms of drugs
  • Exhibit 45: Side effects of immunosuppressants
  • Exhibit 46: Demand-supply imbalance of organ transplantation 2011-2015
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: AbbVie Inc. - Vendor overview
  • Exhibit 54: AbbVie Inc. - Business segments
  • Exhibit 55: AbbVie Inc. - Organizational developments
  • Exhibit 56: AbbVie Inc. - Geographic focus
  • Exhibit 57: AbbVie Inc. - Key offerings
  • Exhibit 58: AbbVie Inc. - Key customers
  • Exhibit 59: Astellas Pharma Inc. - Vendor overview
  • Exhibit 60: Astellas Pharma Inc. - Business segments
  • Exhibit 61: Astellas Pharma Inc. - Organizational developments
  • Exhibit 62: Astellas Pharma Inc. - Geographic focus
  • Exhibit 63: Astellas Pharma Inc. - Key offerings
  • Exhibit 64: Astellas Pharma Inc. - Key customers
  • Exhibit 65: Cadila Healthcare Ltd. - Vendor overview
  • Exhibit 66: Cadila Healthcare Ltd. - Business segments
  • Exhibit 67: Cadila Healthcare Ltd. - Organizational developments
  • Exhibit 68: Cadila Healthcare Ltd. - Geographic focus
  • Exhibit 69: Cadila Healthcare Ltd. - Key offerings
  • Exhibit 70: Cadila Healthcare Ltd. - Key customers
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 78: Mylan NV - Vendor overview
  • Exhibit 79: Mylan NV - Business segments
  • Exhibit 80: Mylan NV - Organizational developments
  • Exhibit 81: Mylan NV - Geographic focus
  • Exhibit 82: Mylan NV - Segment focus
  • Exhibit 83: Mylan NV - Key offerings
  • Exhibit 84: Mylan NV - Key customers
  • Exhibit 85: Novartis AG - Vendor overview
  • Exhibit 86: Novartis AG - Business segments
  • Exhibit 87: Novartis AG - Organizational developments
  • Exhibit 88: Novartis AG - Geographic focus
  • Exhibit 89: Novartis AG - Segment focus
  • Exhibit 90: Novartis AG - Key offerings
  • Exhibit 91: Novartis AG - Key customers
  • Exhibit 92: Pfizer Inc. - Vendor overview
  • Exhibit 93: Pfizer Inc. - Business segments
  • Exhibit 94: Pfizer Inc. - Organizational developments
  • Exhibit 95: Pfizer Inc. - Geographic focus
  • Exhibit 96: Pfizer Inc. - Segment focus
  • Exhibit 97: Pfizer Inc. - Key offerings
  • Exhibit 98: Pfizer Inc. - Key customers
  • Exhibit 99: Sun Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 100: Sun Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 101: Sun Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 102: Sun Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 103: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 104: Sun Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 105: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 106: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 107: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 108: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 109: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 110: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 111: Veloxis Pharmaceuticals A/S - Vendor overview
  • Exhibit 112: Veloxis Pharmaceuticals A/S - Business segments
  • Exhibit 113: Veloxis Pharmaceuticals A/S - Organizational developments
  • Exhibit 114: Veloxis Pharmaceuticals A/S - Geographic focus
  • Exhibit 115: Veloxis Pharmaceuticals A/S - Key offerings
  • Exhibit 116: Veloxis Pharmaceuticals A/S - Key customers
  • Exhibit 117: Validation techniques employed for market sizing
  • Exhibit 118: Definition of market positioning of vendors